连云港市2022—2024年乙型肝炎母婴阻断效果评估及影响因素分析

doi:10.12183/j.scjpm.2026.0942

Abstract

CLC Number:

R512.62

Niu Ying, Zhu Guilian. Effectiveness of and factors influencing the prevention of mother-to-child transmission of hepatitis B in Lianyungang, 2022-2024[J].South China Journal of Preventive Medicine, 2026, 52(8): 942-947.

References

[1] Burki T.WHO's 2024 global hepatitis report[J]. Lancet Infect Dis, 2024, 24(6): e362-e363.
[2] Huang H, Xu C, Liu L, et al.Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus[J]. Clin Infect Dis, 2021, 73(9): e3317-e3323.
[3] Yin X, Wang W, Chen H, et al.Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30(2): 455-462.
[4] Xu B, Xu C, Feng J, et al.Reduced mother-to-child transmission of hepatitis B after implementation of completely charge-free active-passive immunoprophylaxis: An observational cohort study[J]. Expert Rev Vaccines, 2021, 20(7): 899-905.
[5] Wu S, Wang J, Guo Q, et al.Prevalence of human immunodeficiency virus, syphilis, and hepatitis B and C virus infections in pregnant women: A systematic review and meta-analysis[J]. Clin Microbiol Infect, 2023, 29(8): 1000-1007.
[6] Liu J, Wang X, Wang Q, et al.Hepatitis B virus infection among 90 million pregnant women in 2 853 Chinese counties, 2015-2020: A national observational study[J]. Lancet Reg Health West Pac, 2021, 16: 100267.
[7] 黄东旭, 王潇滟, 王前, 等. 2021—2023年中国孕产妇乙型肝炎病毒现症感染的流行病学分析[J]. 中华肝脏病杂志, 2024, 32(5): 449-452.
[8] Lu Y, Song Y, Zhai X, et al.Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus[J]. Emerg Microbes Infect, 2021, 10(1): 555-564.
[9] 李青云, 张雅倩, 秦鑫鑫, 等. 2020—2024年南京地区乙型肝炎母婴阻断效果分析[J]. 华南预防医学, 2025, 51(10): 1144-1147.
[10] Liu D, Liu Y, Ni J, et al.Hepatitis B infection among pregnant women in China: A systematic review and meta-analysis[J]. Front Public Health, 2022, 10: 879289.
[11] Yan R, Sun M, Yang H, et al.2024 latest report on hepatitis B virus epidemiology in China: Current status, changing trajectory, and challenges[J]. Hepatobiliary Surg Nutr, 2025, 14(1): 66-77.
[12] 罗雅丽, 王维, 潘禹辰, 等. 我国消除HBV母婴传播的实施案例与经验介绍[J]. 临床肝胆病杂志, 2024, 40(11): 2145-2151.
[13] 张雪, 陈正超, 李一辰, 等. 10 250例乙型肝炎病毒垂直暴露儿童母婴传播干预效果分析[J]. 中华实验和临床感染病杂志(电子版), 2025, 19(3): 157-164.
[14] 高洁, 杨敏, 吴颖岚, 等. 乙型肝炎阳性孕产妇服务利用情况分析[J]. 中国医师杂志, 2024, 26(12): 1794-1797.
[15] 陈小霞, 林铭镇. 泉州市产妇乙肝感染状况及母婴阻断效果分析[J]. 海峡预防医学杂志, 2023, 29(1): 38-40.
[16] 李健, 王富珍, 陈仲丹, 等. 中国病毒性肝炎疾病负担研究进展[J]. 临床肝胆病杂志, 2025, 41(2): 221-227.
[17] Wang C, Zhang S, Zhao J, et al.Changes and gaps of global and regional disease burden of hepatitis B infection in children younger than 5 years old between 2015 and 2019: A real-world data review[J]. J Med Virol, 2023, 95(11): e29241.
[18] 韩国荣, 江红秀. 妊娠期抗病毒治疗阻断HBV母婴传播的新进展[J]. 临床肝胆病杂志, 2024, 40(11): 2158-2163.
[19] Boucheron P, Lu Y, Yoshida K, et al.Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: A systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21(1): 85-96.
[20] Yao N, Fu S, Wu Y, et al.Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis[J]. Acta Obstet Gynecol Scand, 2022, 101(11): 1197-1206.

Effectiveness of and factors influencing the prevention of mother-to-child transmission of hepatitis B in Lianyungang, 2022-2024

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	. [J]. South China Journal of Preventive Medicine, 2024, 50(3): 274-276.
[2]	. [J]. South China Journal of Preventive Medicine, 2022, 48(10): 1264-1267.
[3]	. [J]. South China Journal of Preventive Medicine, 2022, 48(7): 851-853.
[4]	. [J]. South China Journal of Preventive Medicine, 2022, 48(5): 608-610.
[5]	LIU Min-huan, ZHANG Shi-xi, WANG Cai-xia. Serum inflammatory factor levels and disease progression in patients with chronic hepatitis B virus infection [J]. South China Journal of Preventive Medicine, 2022, 48(4): 438-442.
[6]	ZHOU Cong, CHEN Qiu-yun, LIU Miao-miao. Epidemiological characteristics of hepatitis B in Yangchun City, 2009-2013 [J]. S China J Prev Med, 2016, 42(1): 58-60.
[7]	TAN Qiu, WU Cheng-gang, LIANG Jian,SHAO Xiap-ping. Family aggregation and factor analysis of HBV infection in Guangdong Province [J]. S China J Prev Med, 2014, 40(5): 468-471.
[8]	ZHONG Gui-hong, LIU Yu, SHAO Xiao-ping, ZHENG Hui-zhen. Surveillance of adverse events following hepatitis B vaccine immunization in Guangdong Province, 2009-2012 [J]. S China J Prev Med, 2014, 40(4): 380-383.
[9]	LUO Tao, PAN Hong, HOU Xing-hua, DENG Mao-ming, WU Yun-feng, GUO Yu, DUAN Lin-li, WU Nian-biao, YANG Bin.. Evaluation of MOH/GAVI project for improving timely birth dose coverage of hepatitis B vaccination in Qiandongnan, Guizhou [J]. S China J Prev Med, 2014, 40(1): 25-28.
[10]	. [J]. S China J Prev Med, 2013, 39(5): 44-45.
[11]	ZHAN Liu-hua, ZHOU Wen, XIAO Xiao-ling, DAI Liping; REN Wei; WU Xin-wei; HE Jin-hong; LI Jie-han; WU Chu-xian; LIU Fang-hua; HAO Yuan-tao. Management of integrated prevention and control of hepatitis B in community by using residential electronic health records platform [J]. S China J Prev Med, 2013, 39(4): 88-90.
[12]	FU Zhi-zhi, LV Wei, XU Wu-zhe, REN Mei-xuan．. Epidemiological characteristics of hepatitis B in Guangxi, 2005-2012 [J]. S China J Prev Med, 2013, 39(4): 20-24.
[13]	. [J]. S China J Prev Med, 2013, 39(3): 77-79.
[14]	CAI Li, CAI Lin, DUAN Li-na, FANG Qiong, LIN Bao-ni, ZHOU Zhi-feng. Investigation on status of interrupting maternal-infant transmission of hepatitis B virus in Futian District, Shenzhen City, 2012 [J]. S China J Prev Med, 2013, 39(2): 45-47.
[15]	Guangdong Provincial Center for Disease Control and Prevention. Guidelines for hepatitis B vaccination in Guangdong Province (for trial implementation) [J]. S China J Prev Med, 2013, 39(1): 92-93+97.